| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
Wogonin (Vogonin), a naturally occurring and pharmacologically-active flavonoid found in plants, has been reported to exhibit anticancer effects against various cancer cell types such as osteosarcoma, leukemia, breast cancer and glioma. Wogonin induced a G1 phase cell cycle arrest in HCT116 cells in a concentration- and time-dependent manner. Meanwhile, the cell cycle-related proteins, such as cyclin A, E, D1, and CDK2, 4 were down-regulated in wogonin-induced G1 cell cycle arrest. Furthermore, we showed that the anti-proliferation and G1 arrest effect of wogonin on HCT116 cells was associated with deregulation of Wnt/β-catenin signaling pathway.
| ln Vitro |
In caco-2, SW1116, and HCT116 cells, wogonin (0-200 μM) shows a dose- and time-dependent reduction in cell viability. In HCT-116 cells, wogonin (10–40 μM) causes G1 phase arrest. In HCT116 cells, wogonin also inhibits the Wnt signaling pathway. Wogonin interferes with the TCF/Lef family transcription factor's function. Furthermore, Wogonin suppresses CDK8 activity to prevent β-catenin-mediated transcription[1]. On HeLa cells, wogonin exhibits cytotoxic and antiproliferative properties. In HeLa cells, wogonin (90 µM) significantly reduces the levels of cyclin D1 and Cdk4, and causes cell cycle arrest at the G0-G1 phase[2]. In RAW264.7 cells, wogonin (1.25, 2.5, 5, 10, 20 μg/ml) inhibits the inflammatory response triggered by EtOH[3].
|
||
|---|---|---|---|
| ln Vivo |
Wogonin (30, 60 mg/kg) inhibits HCT116 cell tumor growth in a xenograft model[1]. Wogonin (25, 50, and 100 mg/kg) shields mice's livers from damage and the pathological features of ALD. In mice with ALD and RAW264.7 cells induced by EtOH, wogonin stimulates the expression of PPAR-γ[3].
|
||
| Animal Protocol |
|
||
| References |
[1]. He L, et al. Wogonin induced G1 cell cycle arrest by regulating Wnt/β-catenin signaling pathway and inactivating CDK8 in human colorectal cancer carcinoma cells. Toxicology. 2013 Oct 4;312:36-47.
[2]. Yang L, et al. Wogonin induces G1 phase arrest through inhibiting Cdk4 and cyclin D1 concomitant with an elevation in p21Cip1 in human cervical carcinoma HeLa cells. Biochem Cell Biol. 2009 Dec;87(6):933-42. [3]. Li HD, et al. Wogonin attenuates inflammation by activating PPAR-γ in alcoholic liver disease. Int Immunopharmacol. 2017 Sep;50:95-106 |
| Molecular Formula |
C16H12O5
|
|
|---|---|---|
| Molecular Weight |
284.26
|
|
| CAS # |
632-85-9
|
|
| Related CAS # |
51059-44-0 (Wogonoside)
|
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
|
| SMILES |
O1C(C2C([H])=C([H])C([H])=C([H])C=2[H])=C([H])C(C2C(=C([H])C(=C(C1=2)OC([H])([H])[H])O[H])O[H])=O
|
|
| InChi Key |
XLTFNNCXVBYBSX-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C16H12O5/c1-20-15-12(19)7-10(17)14-11(18)8-13(21-16(14)15)9-5-3-2-4-6-9/h2-8,17,19H,1H3
|
|
| Chemical Name |
4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-methoxy-2-phenyl-
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (7.32 mM) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 24 mg/mL (84.43 mM) in 0.5% CMC-Na/saline water (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5179 mL | 17.5895 mL | 35.1791 mL | |
| 5 mM | 0.7036 mL | 3.5179 mL | 7.0358 mL | |
| 10 mM | 0.3518 mL | 1.7590 mL | 3.5179 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
